Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating concomitant administration of macitentan and dapagliflozin in patients with heart failure with mid-range and preserved ejection fractio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Pre- and Post-capillary Pulmonary Hypertension
• Group Pulmonary Hypertension
• Heart Failure with Mid-range Ejection Fraction
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• FARXIGA (dapagliflozin)
• OPSUMIT (macitentan)

Snippet

Sponsor: Gachon University Gil Medical Center | Conditions: Combined Pre- and Post-capillary Pulmonary Hypertension, CpcPH | Phase 4 | Status: RECRUITING